Better Blood Biomarkers for ME/CFS

Principal Investigator

Recent ME/CFS research focuses on blood biomarkers for diagnosis, prognosis, and treatment monitoring. Immune dysregulation, mitochondrial dysfunction, and metabolic changes are highlighted as key pathways. Omics technologies aid in discovering novel biomarkers and understanding disease heterogeneity. Challenges like sample variation and reproducibility underscore the importance of collaboration and standardization. Despite obstacles, biomarker discovery offers potential for early detection, personalized treatment, and better outcomes. This research signals a move towards precision medicine in ME/CFS management, promising transformative impact in clinical practice.

07 Jun 2024 - 30 Jun 2027

N/A